US 12,723,067 B2 · Human interleukin-2 variant or derivative thereof

Abstract

Provided is a human interleukin-2 (IL-2) variant having one or more amino acid mutations or a derivative thereof. The IL-2 variant or derivative thereof has increased stability compared to wild-type IL-2 and improved properties as an immunotherapeutic agent. Also disclosed are an immunoconjugate and a pharmaceutical composition which comprise the human IL-2 variant or derivative thereof, a polynucleotide molecule encoding same, a vector, a host cell and a preparation method therefor, as well as the pharmaceutical uses of the IL-2 variant or derivative thereof and the immunoconjugate or pharmaceutical composition comprising the L-2 variant or derivative thereof.

Claims4

Dependent claims

An IL-2 variant consisting of mutations selected from:

(i) N26Q, N29S, F42A, N71Q and L72G;
or
(ii) N26Q, N29S, F42A, N71Q, L72G and C125A;
wherein the mutations thereof are relative to a wild type IL-2, the amino acid sequence of which is as shown in SEQ ID NO:
2, and the numbering of the mutation position is counted from the amino acid A at the second position according to the amino acid sequence shown in SEQ ID NO:
2.

3 more elements

Dependencies are inferred from the claim text.

Human interleukin-2 variant or derivative thereof

Life of this patent

Human interleukin-2 variant or derivative thereof

Life of this patent

Abstract

Claims4